Newly diagnosed chronic granulomatous disease in a 44 year old male presenting with recurrent groin cellulitis and colitis
© Chung et al; licensee BioMed Central Ltd. 2013
Received: 27 July 2012
Accepted: 28 January 2013
Published: 6 March 2013
Chronic Granulomatous Disease (CGD) is an inherited deficiency which results from the absence or dysfunction of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits in phagocytic cells. This condition is usually diagnosed in early childhood and presents with recurrent infections at epithelial surfaces such as the skin, lungs, and gut. We present a case of CGD which was diagnosed late in adulthood.
A forty-four year old male was admitted to hospital with fever, testicular pain and an acute onset of swelling of his penis and scrotum.
His past history was significant for Crohn’s disease diagnosed at age sixteen; stable on treatment with mesalamine (Asacol®). He also had recurrent soft tissue infections of his penis and/or scrotum since childhood, approximately 2 or 3 in total, to his recollection. There was no history of abscesses or sexually transmitted infections. However, the patient did complain of frequent upper respiratory tract infections each winter. He had no family history of primary immunodeficiency disease.
Results of Immunologic Investigations
7.8 × 109/L
4.0 – 11.0 × 109/L
4 – 26%
0.87 × 109/L
0.50 – 1.75 × 109/L
0.32 × 109/L
0.15 – 0.84 × 109/L
0.70 – 3.52 g/L
6.35 – 14.65 g/L
0.41 – 2.07 g/L
Absence of Oxidative Burst Response
Quantitative dihydrorhodamine (DHR)123 flow cytometry assay revealed the complete absence of an oxidative burst response; this was confirmed three times. This was suggestive of a neutrophil NADPH oxidase deficiency associated with CGD.
The patient was treated with intravenous cefazolin and metronidazole and discharged home on clindamycin. His cellulitis resolved within weeks, but he experienced a recurrence approximately 6 months later. He was started on trimethoprim-sulfamethoxazole (TMP-SMX), amoxicillin, and itraconazole as prophylactic therapy to prevent future infections. He was assessed by the Infectious Disease service, who simplified his prophylactic regimen to TMP-SMX 160/800 q Mon/Wed/Fri and Penicillin V K 300mg OD based on risk assessment and previous infective patterns. Interferon-gamma was considered, but based on restricted availability at the time and his relatively stable clinical course to date, we elected to pursue antibiotic prophylaxis and active surveillance alone.
Genetic testing, performed by the Hospital for Sick Children in Toronto, confirmed a diagnosis of CGD and revealed a homozygous mutation in the NCFI gene (P47). It was recommended that directly family members receive DHR flow cytometry screening but this was declined.
CGD is a rare disorder with an approximate incidence of 1 in 200,000 births. A mutation in one of four protein subunits of the NADPH oxidase complex (gp91-, p22-, p47-, p67-phox) result in CGD. The NADPH oxidase enzyme complex is responsible for production of superoxide anions required for a cellular respiratory burst. Patients deficient in the NADPH oxidase enzyme become susceptible to recurrent life-threatening infections by a spectrum of fungi and bacteria, most commonly Aspergillus and Staphyloccocus spp. There are 410 known mutations of the 4 affected genes with 76% related to a mutation of gp91-phox, the x-linked recessive form. The p47-phox mutation occurs in 18%, while the p67 and p22 mutations are less common (4 and 3%, respectively).
The most common infections in CGD include pneumonia, abscess and suppurative adenitis (79%, 68%, and 53% respectively), while cellulitis occurs in only 10%. CGD can also present with a granulomatous colitis mimicking Crohn’s disease in 17%.
CGD patients can be vaccinated with measles, varicella and annual influenzae, but BCG should be avoided because of the risk of developing disseminated BCG-osis. Prophylactic antibiotics and anti-fungal agents such as trimethoprim-sulfamethoxazole and itraconazole have been found in small studies to reduce rates of infections, surgical interventions and hospitalization[3, 4]. Prophylactic IFN-γ given thrice weekly may reduce the risk of serious infections. Bone marrow transplantation provides definitive treatment but is reserved for the most severe cases and gene therapy with retroviral vectors may be a promising solution in the future.
CGD is usually diagnosed in childhood. The mean age of diagnosis for the x-linked recessive form is 3 years of age while the autosomal recessive forms are diagnosed at 7.8 years of age. A small number of CGD cases have been diagnosed in adulthood beyond the fourth decade[7–10]; the oldest case report identified in the English language literature was of a male diagnosed at 69 years of age.
In summary, we present a patient who was diagnosed with CGD in adulthood with manifestations limited to recurrent scrotal cellulitis and a granulomatous colitis, which was initially misdiagnosed as Crohn’s disease. Adults with a history of recurrent infections, particularly in atypical anatomic locations, in the absence of obvious secondary immunodeficient states (e.g. diabetes mellitus, corticosteroid use) should prompt an evaluation for underlying immunodeficiency, regardless of the age at presentation.
Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Chronic granulomatous disease
Nicotinamide adenine dinucleotide phosphate.
- Winkelstein JA, Marino MC, Johnston RB: Chronic granulomatous disease: report on a national registry of 368 patients. Medicine. 2000, 79: 155-169. 10.1097/00005792-200005000-00003.View ArticlePubMedGoogle Scholar
- Bustamante J, Aksu G, Vogt G: BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol. 2007, 120: 32-38. 10.1016/j.jaci.2007.04.034.View ArticlePubMedGoogle Scholar
- Margolis DM, Melnick DA, Alling DW: Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990, 162: 723-726. 10.1093/infdis/162.3.723.View ArticlePubMedGoogle Scholar
- Gallin JI, Alling DW, Malech HL: Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003, 348: 2416-2422. 10.1056/NEJMoa021931.View ArticlePubMedGoogle Scholar
- The International Chronic Granulomatous Disease Cooperative Study Group: A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991, 324: 509-516.View ArticleGoogle Scholar
- Seger R: Modern Management of Chronic Granulomatous Disease. Br J Haematol. 2008, 140: 255-266. 10.1111/j.1365-2141.2007.06880.x.View ArticlePubMedGoogle Scholar
- Wolach B, Scharf Y, Gavrieli R: Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB. Blood. 2005, 105 (1): 61-66. 10.1182/blood-2004-02-0675.View ArticlePubMedGoogle Scholar
- Ramanuja S, Wolf KM, Sadat MA: Newly diagnosed chronic granulomatous disease in a 53-year-old woman with Crohn disease. Ann Allergy Asthma Immunol. 2005, 95 (2): 204-209. 10.1016/S1081-1206(10)61212-4.View ArticlePubMedGoogle Scholar
- Gono T, Yazaki M, Agematsu K: Adult onset X-linked chronic granulomatous disease in a woman patient caused by a de novo mutation in paternal-origin CYBB gene and skewed inactivation of normal maternal X chromosome. Intern Med. 2008, 47 (11): 1053-1056. 10.2169/internalmedicine.47.0919.View ArticlePubMedGoogle Scholar
- Roesler J, Segerer F, Morbach H: P67-phox (NCF2) lacking exons 11 and 12 is functionally active and leads to an extremely late diagnosis of chronic granulomatous disease (CGD). PLoS One. 2012, 7 (4): e34296-10.1371/journal.pone.0034296.PubMed CentralView ArticlePubMedGoogle Scholar
- Schapiro BL, Newburger PE, Klempner MS: Chronic granulomatous disease presenting in a 69-year-old man. N Engl J Med. 1991, 325: 1786-1790. 10.1056/NEJM199112193252506.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.